Insider Trading activities of Oncomed Pharmaceuticals Inc insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Oncomed Pharmaceuticals Inc since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Oncomed Pharmaceuticals Inc since year 2005. Table 2 shows the detailed insider transactions of Oncomed Pharmaceuticals Inc since 2005. The reporting company's ticker symbol is OMED. The reporting company's CIK number is 1302573.
The total value of stock buying since 2005 is $23,268,721.
The total value of stock sales since 2005 is $14,677,041.
The total value of stock option exercises since 2005 is $609,758.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Oncomed Pharmaceuticals Inc (OMED).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2017-10 0 $0 6,390 $27,174 0 $0
2017-06 10,000 $34,590 0 $0 0 $0
2017-05 78,121 $269,711 28,267 $103,867 0 $0
2017-04 0 $0 33,805 $303,023 0 $0
2017-03 0 $0 6,652 $66,520 6,652 $22,749
2017-01 0 $0 64,676 $524,049 64,676 $92,485
2016-11 0 $0 12,500 $123,612 12,500 $17,875
2016-01 0 $0 17,345 $375,593 2,500 $11,399
2015-12 0 $0 2,500 $51,232 2,500 $11,399
2015-11 0 $0 4,300 $94,575 4,300 $17,555
2015-10 0 $0 24,400 $493,400 10,400 $41,267
2015-09 24,350 $366,668 0 $0 0 $0
2015-08 0 $0 2,500 $55,622 2,500 $11,399
2015-07 0 $0 20,800 $434,622 6,800 $28,954
2015-06 0 $0 23,800 $597,262 23,800 $46,073
2015-05 0 $0 5,800 $132,567 1,800 $6,156
2015-04 0 $0 31,187 $797,515 25,300 $44,455
2015-03 0 $0 23,500 $649,943 19,500 $68,398
2015-02 0 $0 17,000 $403,035 13,000 $23,284
2015-01 0 $0 17,000 $394,392 13,000 $46,759
2014-12 0 $0 121,052 $2,614,327 4,000 $5,720
2014-11 0 $0 10,500 $211,245 6,500 $9,295
2014-10 0 $0 30,578 $645,201 22,578 $32,285
2014-09 3,170 $58,174 2,191 $43,830 2,191 $3,133
2014-08 81,248 $1,539,614 10,500 $218,789 6,500 $9,295
2014-07 0 $0 26,270 $586,483 22,270 $36,539
2014-06 0 $0 114,902 $2,776,440 5,500 $12,559
2014-05 0 $0 77,783 $1,736,318 2,500 $3,575
2014-03 0 $0 1,792 $64,180 0 $0
2014-02 0 $0 5,000 $152,225 5,000 $7,150
2013-07 1,235,292 $20,999,964 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Oncomed Pharmaceuticals Inc insiders (OMED)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2017-10-10 Hager Alicia J. (SVP & General Counsel) Sale 1,248 4.25 5,305
2017-10-10 Gurney Austin (See Remarks) Sale 1,248 4.26 5,311
2017-10-10 Lewicki John A. (EVP, Research & Development) Sale 1,248 4.25 5,305
2017-10-10 Patel Sunil (See Remarks) Sale 1,248 4.26 5,311
2017-10-10 Hastings Paul J (Chairman & CEO) Sale 1,398 4.25 5,942
2017-06-05 Karsen Perry A Buy 10,000 3.46 34,590
2017-05-26 Root Jonathan D (Director) Sale 9,580 3.70 35,465
2017-05-25 Lasersohn Jack W Buy 34,614 3.37 116,649
2017-05-24 Root Jonathan D (Director) Sale 4,300 3.72 15,978
2017-05-23 Lasersohn Jack W Buy 20,000 3.55 71,000
2017-05-19 Root Jonathan D (Director) Sale 7,487 3.70 27,709
2017-05-16 Root Jonathan D (Director) Sale 6,900 3.58 24,715
2017-05-16 Lasersohn Jack W Buy 23,507 3.49 82,062
2017-04-04 Hager Alicia J. (SVP & General Counsel) Sale 4,316 8.97 38,697
2017-04-04 Gurney Austin (See Remarks) Sale 5,754 8.96 51,573
2017-04-04 Lewicki John A. (EVP, Research & Development) Sale 5,754 8.96 51,573
2017-04-04 Hoey Timothy (SVP, Cancer Biology & Co-CSO) Sale 5,754 8.96 51,573
2017-04-04 Patel Sunil (See Remarks) Sale 5,754 8.97 51,590
2017-04-04 Hastings Paul J (Chairman & CEO) Sale 6,473 8.96 58,017
2017-03-15 Hager Alicia J. (SVP & General Counsel) Sale 6,652 10.00 66,520
2017-03-15 Hager Alicia J. (SVP & General Counsel) Option Ex 6,652 3.42 22,749
2017-01-06 Hastings Paul J (Chairman & CEO) Sale 21,369 8.52 181,957
2017-01-06 Hastings Paul J (Chairman & CEO) Option Ex 21,369 1.43 30,557
2017-01-05 Hastings Paul J (Chairman & CEO) Sale 21,369 8.17 174,606
2017-01-05 Hastings Paul J (Chairman & CEO) Option Ex 21,369 1.43 30,557
2017-01-03 Lewicki John A. (EVP, Research & Development) Sale 9,175 7.63 70,041
2017-01-03 Lewicki John A. (EVP, Research & Development) Option Ex 9,175 1.43 13,120
2017-01-03 Hoey Timothy (SVP, Cancer Biology & Co-CSO) Sale 12,763 7.63 97,445
2017-01-03 Hoey Timothy (SVP, Cancer Biology & Co-CSO) Option Ex 12,763 1.43 18,251
2016-11-16 Hoey Timothy (SVP, Cancer Biology & Co-CSO) Sale 12,500 9.89 123,612
2016-11-16 Hoey Timothy (SVP, Cancer Biology & Co-CSO) Option Ex 12,500 1.43 17,875
2016-01-11 Dupont Jakob (SVP & Chief Medical Officer) Sale 2,500 20.01 50,020
2016-01-11 Dupont Jakob (SVP & Chief Medical Officer) Option Ex 2,500 4.56 11,399
2016-01-07 Hager Alicia J. (VP & General Counsel) Sale 1 21.33 21
2016-01-07 Gurney Austin (See Remarks) Sale 1 21.33 21
2016-01-07 Lewicki John A. (EVP & Chief Scientific Officer) Sale 1 21.33 21
2016-01-07 Dupont Jakob (SVP & Chief Medical Officer) Sale 1 21.33 21
2016-01-07 Hoey Timothy (SVP, Cancer Biology) Sale 1 21.33 21
2016-01-07 Patel Sunil (See Remarks) Sale 1 21.33 21
2016-01-06 Hager Alicia J. (VP & General Counsel) Sale 1,622 21.92 35,557
2016-01-06 Gurney Austin (See Remarks) Sale 2,161 21.92 47,369
2016-01-06 Lewicki John A. (EVP & Chief Scientific Officer) Sale 2,161 21.93 47,395
2016-01-06 Dupont Jakob (SVP & Chief Medical Officer) Sale 2,161 21.92 47,369
2016-01-06 Hoey Timothy (SVP, Cancer Biology) Sale 2,161 21.93 47,390
2016-01-06 Patel Sunil (See Remarks) Sale 2,161 21.98 47,492
2016-01-06 Hastings Paul J (Chairman & CEO) Sale 2,412 21.92 52,875
2015-12-10 Dupont Jakob (SVP & Chief Medical Officer) Sale 2,500 20.49 51,232
2015-12-10 Dupont Jakob (SVP & Chief Medical Officer) Option Ex 2,500 4.56 11,399
2015-11-27 Hager Alicia J. (VP & General Counsel) Sale 1,800 23.14 41,653
2015-11-27 Hager Alicia J. (VP & General Counsel) Option Ex 1,800 3.42 6,156
2015-11-10 Dupont Jakob (SVP & Chief Medical Officer) Sale 2,500 21.17 52,922
2015-11-10 Dupont Jakob (SVP & Chief Medical Officer) Option Ex 2,500 4.56 11,399
2015-10-27 Hager Alicia J. (VP & General Counsel) Sale 5,400 21.00 113,400
2015-10-27 Hager Alicia J. (VP & General Counsel) Option Ex 5,400 3.42 18,468
2015-10-26 Gurney Austin (See Remarks) Sale 14,000 20.00 280,000
2015-10-26 Dupont Jakob (SVP & Chief Medical Officer) Sale 5,000 20.00 100,000
2015-10-26 Dupont Jakob (SVP & Chief Medical Officer) Option Ex 5,000 4.56 22,799
2015-09-30 Lasersohn Jack W Buy 11,210 15.60 174,887
2015-09-29 Lasersohn Jack W Buy 3,140 14.15 44,431
2015-09-28 Lasersohn Jack W Buy 10,000 14.73 147,350
2015-08-10 Dupont Jakob (SVP & Chief Medical Officer) Sale 2,500 22.25 55,622
2015-08-10 Dupont Jakob (SVP & Chief Medical Officer) Option Ex 2,500 4.56 11,399
2015-07-30 Gurney Austin (See Remarks) Sale 7,000 21.24 148,687
2015-07-29 Gurney Austin (See Remarks) Sale 7,000 20.68 144,760
2015-07-28 Hager Alicia J. (VP & General Counsel) Sale 1,800 21.00 37,800
2015-07-28 Hager Alicia J. (VP & General Counsel) Option Ex 1,800 3.42 6,156
2015-07-10 Dupont Jakob (SVP & Chief Medical Officer) Sale 2,500 20.13 50,325
2015-07-10 Dupont Jakob (SVP & Chief Medical Officer) Option Ex 2,500 4.56 11,399
2015-07-06 Dupont Jakob (SVP & Chief Medical Officer) Sale 2,500 21.22 53,050
2015-07-06 Dupont Jakob (SVP & Chief Medical Officer) Option Ex 2,500 4.56 11,399
2015-06-29 Hager Alicia J. (VP & General Counsel) Sale 1,800 22.66 40,797
2015-06-29 Hager Alicia J. (VP & General Counsel) Option Ex 1,800 3.42 6,156
2015-06-22 Hoey Timothy (SVP, Cancer Biology) Sale 5,000 26.07 130,335
2015-06-22 Hoey Timothy (SVP, Cancer Biology) Option Ex 5,000 1.43 7,150
2015-06-16 Lewicki John A. (EVP & Chief Scientific Officer) Sale 8,500 25.22 214,336
2015-06-16 Lewicki John A. (EVP & Chief Scientific Officer) Option Ex 8,500 2.42 20,612
2015-06-15 Lewicki John A. (EVP & Chief Scientific Officer) Sale 8,500 24.92 211,794
2015-06-15 Lewicki John A. (EVP & Chief Scientific Officer) Option Ex 8,500 1.43 12,155
2015-05-27 Hager Alicia J. (VP & General Counsel) Sale 1,800 23.07 41,527
2015-05-27 Hager Alicia J. (VP & General Counsel) Option Ex 1,800 3.42 6,156
2015-05-18 Gurney Austin (See Remarks) Sale 4,000 22.76 91,040
2015-04-27 Hager Alicia J. (VP & General Counsel) Sale 1,800 25.68 46,218
2015-04-27 Hager Alicia J. (VP & General Counsel) Option Ex 1,800 3.42 6,156
2015-04-27 Hoey Timothy (SVP, Cancer Biology) Sale 6,887 25.66 176,747
2015-04-27 Hoey Timothy (SVP, Cancer Biology) Option Ex 5,000 1.43 7,150
2015-04-17 Gurney Austin (See Remarks) Sale 4,000 26.00 103,980
2015-04-10 Dupont Jakob (SVP & Chief Medical Officer) Sale 1,500 26.51 39,765
2015-04-10 Dupont Jakob (SVP & Chief Medical Officer) Option Ex 1,500 4.56 6,839
2015-04-02 Lewicki John A. (EVP & Chief Scientific Officer) Sale 8,500 25.49 216,699
2015-04-02 Lewicki John A. (EVP & Chief Scientific Officer) Option Ex 8,500 1.43 12,155
2015-04-01 Lewicki John A. (EVP & Chief Scientific Officer) Sale 8,500 25.19 214,106
2015-04-01 Lewicki John A. (EVP & Chief Scientific Officer) Option Ex 8,500 1.43 12,155
2015-03-20 Patel Sunil (See Remarks) Sale 14,665 27.86 408,537
2015-03-20 Patel Sunil (See Remarks) Option Ex 14,665 3.42 50,154
2015-03-19 Patel Sunil (See Remarks) Sale 3,335 27.34 91,185
2015-03-19 Patel Sunil (See Remarks) Option Ex 3,335 3.42 11,405
2015-03-17 Gurney Austin (See Remarks) Sale 4,000 27.37 109,468
2015-03-10 Dupont Jakob (SVP & Chief Medical Officer) Sale 1,500 27.17 40,753
2015-03-10 Dupont Jakob (SVP & Chief Medical Officer) Option Ex 1,500 4.56 6,839
2015-02-17 Gurney Austin (See Remarks) Sale 4,000 26.37 105,492
2015-02-10 Dupont Jakob (SVP & Chief Medical Officer) Sale 1,500 24.23 36,351
2015-02-10 Dupont Jakob (SVP & Chief Medical Officer) Option Ex 1,500 4.56 6,839
2015-02-05 Hoey Timothy (SVP, Cancer Biology) Sale 7,500 22.83 171,240
2015-02-05 Hoey Timothy (SVP, Cancer Biology) Option Ex 7,500 1.43 10,725
2015-02-02 Lewicki John A. (EVP & Chief Scientific Officer) Sale 4,000 22.49 89,952
2015-02-02 Lewicki John A. (EVP & Chief Scientific Officer) Option Ex 4,000 1.43 5,720
2015-01-20 Gurney Austin (See Remarks) Sale 4,000 23.27 93,076
2015-01-12 Dupont Jakob (SVP & Chief Medical Officer) Sale 1,500 26.12 39,184
2015-01-12 Dupont Jakob (SVP & Chief Medical Officer) Option Ex 1,500 4.56 6,839
2015-01-05 Dupont Jakob (SVP & Chief Medical Officer) Sale 7,500 23.00 172,500
2015-01-05 Dupont Jakob (SVP & Chief Medical Officer) Option Ex 7,500 4.56 34,200
2015-01-02 Lewicki John A. (EVP & Chief Scientific Officer) Sale 4,000 22.41 89,632
2015-01-02 Lewicki John A. (EVP & Chief Scientific Officer) Option Ex 4,000 1.43 5,720
2014-12-31 Pollard-knight Denise Sale 3,799 21.66 82,301
2014-12-30 Pollard-knight Denise Sale 5,510 21.65 119,285
2014-12-29 Pollard-knight Denise Sale 9,902 21.62 214,051
2014-12-26 Pollard-knight Denise Sale 2,195 21.65 47,517
2014-12-19 Pollard-knight Denise Sale 20,654 21.71 448,315
2014-12-18 Root Jonathan D (Director) Sale 13,052 21.05 274,783
2014-12-17 Gurney Austin (See Remarks) Sale 4,000 20.00 80,000
2014-12-10 Pollard-knight Denise Sale 7,940 21.77 172,885
2014-12-09 Pollard-knight Denise Sale 23,273 21.78 506,979
2014-12-08 Pollard-knight Denise Sale 1,727 21.68 37,434
2014-12-05 Pollard-knight Denise Sale 25,000 21.84 546,025
2014-12-01 Lewicki John A. (EVP & Chief Scientific Officer) Sale 4,000 21.19 84,752
2014-12-01 Lewicki John A. (EVP & Chief Scientific Officer) Option Ex 4,000 1.43 5,720
2014-11-17 Gurney Austin (See Remarks) Sale 4,000 20.16 80,660
2014-11-05 Hoey Timothy (SVP, Cancer Biology) Sale 2,500 19.51 48,765
2014-11-05 Hoey Timothy (SVP, Cancer Biology) Option Ex 2,500 1.43 3,575
2014-11-03 Lewicki John A. (EVP & Chief Scientific Officer) Sale 4,000 20.45 81,820
2014-11-03 Lewicki John A. (EVP & Chief Scientific Officer) Option Ex 4,000 1.43 5,720
2014-10-29 Hastings Paul J (Chairman & CEO) Sale 8,385 21.90 183,614
2014-10-29 Hastings Paul J (Chairman & CEO) Option Ex 8,385 1.43 11,990
2014-10-28 Hastings Paul J (Chairman & CEO) Sale 8,384 22.08 185,127
2014-10-28 Hastings Paul J (Chairman & CEO) Option Ex 8,384 1.43 11,989
2014-10-17 Gurney Austin (See Remarks) Sale 4,000 20.07 80,280
2014-10-02 Gurney Austin (See Remarks) Sale 4,000 20.00 80,000
2014-10-02 Lewicki John A. (EVP & Chief Scientific Officer) Sale 5,809 20.00 116,180
2014-10-02 Lewicki John A. (EVP & Chief Scientific Officer) Option Ex 5,809 1.43 8,306
2014-09-04 Lasersohn Jack W Buy 170 17.50 2,975
2014-09-03 Lasersohn Jack W Buy 3,000 18.40 55,199
2014-09-02 Lewicki John A. (EVP & Chief Scientific Officer) Sale 2,191 20.00 43,830
2014-09-02 Lewicki John A. (EVP & Chief Scientific Officer) Option Ex 2,191 1.43 3,133
2014-08-22 Gurney Austin (See Remarks) Sale 4,000 20.00 80,000
2014-08-21 Pakianathan Deepika (Director) Buy 21,603 18.98 409,981
2014-08-20 Pakianathan Deepika (Director) Buy 46,059 19.00 874,982
2014-08-19 Pakianathan Deepika (Director) Buy 12,541 18.89 236,886
2014-08-15 Lasersohn Jack W Buy 1,045 17.00 17,765
2014-08-05 Hoey Timothy (SVP, Cancer Biology) Sale 2,500 21.95 54,877
2014-08-05 Hoey Timothy (SVP, Cancer Biology) Option Ex 2,500 1.43 3,575
2014-08-01 Lewicki John A. (EVP & Chief Scientific Officer) Sale 4,000 20.98 83,912
2014-08-01 Lewicki John A. (EVP & Chief Scientific Officer) Option Ex 4,000 1.43 5,720
2014-07-29 Hastings Paul J (Chairman & CEO) Sale 8,385 22.28 186,801
2014-07-29 Hastings Paul J (Chairman & CEO) Option Ex 8,385 1.43 11,990
2014-07-28 Hastings Paul J (Chairman & CEO) Sale 8,385 22.31 187,102
2014-07-28 Hastings Paul J (Chairman & CEO) Option Ex 8,385 1.43 11,990
2014-07-23 Dupont Jakob (SVP & Chief Medical Officer) Sale 1,500 23.00 34,500
2014-07-23 Dupont Jakob (SVP & Chief Medical Officer) Option Ex 1,500 4.56 6,839
2014-07-17 Gurney Austin (See Remarks) Sale 4,000 20.46 81,852
2014-07-01 Lewicki John A. (EVP & Chief Scientific Officer) Sale 4,000 24.06 96,228
2014-07-01 Lewicki John A. (EVP & Chief Scientific Officer) Option Ex 4,000 1.43 5,720
2014-06-30 Pollard-knight Denise Sale 11,485 23.59 270,919
2014-06-26 Dupont Jakob (SVP & Chief Medical Officer) Sale 1,500 23.00 34,503
2014-06-26 Dupont Jakob (SVP & Chief Medical Officer) Option Ex 1,500 4.56 6,839
2014-06-25 Pollard-knight Denise Sale 3,252 23.56 76,623
2014-06-24 Pollard-knight Denise Sale 11,764 23.57 277,324
2014-06-23 Pollard-knight Denise Sale 52,797 24.20 1,277,423
2014-06-17 Gurney Austin (See Remarks) Sale 4,000 24.99 99,964
2014-06-16 Lewicki John A. (EVP & Chief Scientific Officer) Sale 4,000 24.59 98,348
2014-06-16 Lewicki John A. (EVP & Chief Scientific Officer) Option Ex 4,000 1.43 5,720
2014-06-10 Root Jonathan D (Director) Sale 4,800 24.48 117,504
2014-06-10 Usvp Entrepreneur Partners Viii B L P (10% Owner) Sale 4,800 24.48 117,504
2014-06-09 Root Jonathan D (Director) Sale 8,252 24.62 203,164
2014-06-09 Usvp Entrepreneur Partners Viii B L P (10% Owner) Sale 8,252 24.62 203,164
2014-05-15 Federman Irwin (10% Owner) Sale 28,956 22.51 651,799
2014-05-12 Young Philip M (10% Owner) Sale 46,327 21.98 1,018,499
2014-05-05 Hoey Timothy (SVP, Cancer Biology) Sale 2,500 26.41 66,020
2014-05-05 Hoey Timothy (SVP, Cancer Biology) Option Ex 2,500 1.43 3,575
2014-03-05 Hoey Timothy (SVP, Cancer Biology) Sale 1,792 35.81 64,180
2014-02-05 Hoey Timothy (SVP, Cancer Biology) Sale 5,000 30.45 152,225
2014-02-05 Hoey Timothy (SVP, Cancer Biology) Option Ex 5,000 1.43 7,150
2013-07-23 Broderick James W. (Director) Buy 70,588 17.00 1,199,996
2013-07-23 Woody James N. (Director) Buy 88,235 17.00 1,499,995
2013-07-23 Morgenthaler Management Partners Vii, Llc (10% Owner) Buy 70,588 17.00 1,199,996
2013-07-23 Rust Christopher J (10% Owner) Buy 158,823 17.00 2,699,991
2013-07-23 Pollard-knight Denise (Director) Buy 58,824 17.00 1,000,008
2013-07-23 Pakianathan Deepika (Director) Buy 382,353 17.00 6,500,001
2013-07-23 Root Jonathan D (Director) Buy 158,823 17.00 2,699,991
2013-07-23 Latterell Patrick F (10% Owner) Buy 88,235 17.00 1,499,995
2013-07-23 Young Philip M (10% Owner) Buy 158,823 17.00 2,699,991

Insider trading activities including stock purchases, stock sales, and option exercises of OMED listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Oncomed Pharmaceuticals Inc (symbol OMED, CIK number 1302573) see the Securities and Exchange Commission (SEC) website.